Glycolipid Disialoganglioside-directed Antibody Interactions [MoA]: Side Effects & Safety Data for 2 Drugs
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
Glycolipid Disialoganglioside-directed Antibody Interactions [MoA] includes 2 drugs with a combined 721 adverse event reports in the FDA FAERS database. Compare their safety profiles, side effects, and outcomes below.
2
Drugs in Class
721
Combined Reports
All Glycolipid Disialoganglioside-directed Antibody Interactions [MoA] Drugs Ranked by Reports
| Drug | Brand Name | Reports | Deaths | Hosp. | Death Rate |
|---|---|---|---|---|---|
| DINUTUXIMAB | Unituxin | 676 | 141 | 247 | 20.9% |
| NAXITAMAB | DANYELZA | 45 | 4 | 18 | 8.9% |
Common Side Effects in Glycolipid Disialoganglioside-directed Antibody Interactions [MoA] Drugs
| Side Effect | Reports | Deaths |
|---|---|---|
| Pyrexia | 151 | 38 |
| Off label use | 95 | 17 |
| Pain | 81 | 5 |
| Neuroblastoma recurrent | 76 | 49 |
| Abdominal pain | 60 | 17 |
| Hypotension | 60 | 11 |
| Neuroblastoma | 49 | 30 |
| Anaemia | 47 | 24 |
| Aspartate aminotransferase increased | 46 | 11 |
| Alanine aminotransferase increased | 43 | 9 |